Source: MarketScreener

Zosano Pharma: Zosano Pharma to showcase new post-hoc analyses of Qtrypta's (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society's Virtual Annual Scientific Meeting Platform

(marketscreener.com) FREMONT, Calif., June 13, 2020 -- Zosano Pharma Corporation , a clinical-stage biopharmaceutical company, today announced that new post-hoc efficacy analyses of QtryptaTM, Zosano's lead investigational product candidate for the acute treatment of migraine, will be presented as a virtual oral presentation on the 2020 American...https://www.marketscreener.com/ZOSANO-PHARMA-CORPORATION-40511999/news/Zosano-Pharma-to-showcase-new-post-hoc-analyses-of-Qtrypta-s-M207-clinical-trial-data-comparing-ke-30768739/?utm_medium=RSS&utm_content=20200613

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating

83/100

Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more